Nobody likes ETFs (and other tales)

REKENTHALER REPORT: Morningstar's Vice President of Research muses on the diverging reports on ETF popularity

John Rekenthaler 12 November, 2009 | 11:26AM
Facebook Twitter LinkedIn

The fund industry daily, Ignites, informs me via my morning e-mail: Advisors Not Buying ETF Hype, Sticking with Active Funds. That's curious in that every month, ETFs attract more assets, Morningstar's ETF coverage gains more readers, and I hear from I don't know how many advisors who have questions about ETFs, because they're incorporating them into their practices.

So I read the article. "In a survey of more than 400 advisors, Cerulli found that nearly 45% said they prefer using actively managed funds in their clients' portfolios rather than primarily passive ETF products."

Silly me, I had thought the elections were over.

Speaking of the Morningstar ETF team, they might have been coming on a bit high in writing that Schwab's low-cost, no-commission-fee ETFs was a "shot heard around the world." It's a fine offer yes, but how long will it last? Schwab's NTF (no transaction fee) fund program was launched with a cost of 25 basis points per year to the underlying funds, and the strongest language this side of binding that the fee structure would stay that way. The NTF program is now at 40 basis points, fellas. No doubt, Schwab's ETF prices will also go where the market will bear.

For hyperbole, however, a shot heard around the world can't touch the Target Date Manifesto, headlined "Retirees Lose Millions in 'Target Death Funds.'" (Fleetingly, that had me thinking about Central American death squads. Which got me musing about Sandinistas. Thus, the Clash. Then "London Calling" began to ring in my head. But I digress.)

Reading about how target-date funds are "fatally flawed" (more corpses), I wondered just how badly target-date funds have fared. Over the trailing 12 months, the average 2010 target date fund is up 21.5%. If that's death, then let me die 1,000 sweet deaths, Juliet.

The next time I see "New Normal" on a Morningstar headline will be one time too many. All right, several times.

This article was first published as part of John Rekenthaler's blog on Morningstar.com.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

John Rekenthaler

John Rekenthaler  John Rekenthaler is vice president of research for Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures